Multimodality Management of Resectable Gastric Cancer: A Review

World Journal of Gastrointestinal Oncology

Volumn 6, Issue , 2014, Pages 393-402

  Shum, Helen ^a   Rajdev, Lakshmi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant chemoradiation; Adjuvant chemotherapy; Gastric adenocarcinoma; Gastric cancer; Neoadjuvant chemotherapy

Indexed keywords

EID: 84922263880     PISSN: None     EISSN: 19485204     Source Type: Journal    
DOI: 10.4251/wjgo.v6.i10.393     Document Type: Article

References (54)

1. 1 World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide; 2012
2. 2 Dubecz A, Solymosi N, Stadihuber RJ, Schweigert M, Stein HJ, Peters JH. Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. J Gastro- intest Surg 2013[Epub ahead of print] [PMID: 24234242]
3. 3 Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014; 23: 700-713 [PMID: 24618998 DOI: 10.1158/1055-9965]
4. 4 Hsu C, Shen YC, Cheng CC, Cheng AL, Hu FC, Yeh KH. Geo–graphic difference in safety and efficacy of systemicchemo- therapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression. Gastric Cancer 2012; 15: 265-280 [PMID: 22576708 DOI: 10.1007/s10120-012-0151-8]
5. 5 Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol 2013; 88: 416-426 [PMID: 23764501 DOI: 10.1016/j.critrevonc.2013.05.007]
6. 6 Rudiger Siewert J, Feith M, Werner M, Stein HJ. Adenocar–cinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232: 353-361 [PMID: 10973385]
7. 7 Gee DW, Rattner DW. Management of gastroesophageal tumors. Oncologist 2007; 12: 175-185 [PMID: 17296813]
8. 8 Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds). AJCC Cancer Staging Manual. 7th Edition. New York: Springer New York, 2009
9. 9 Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gen- nari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230: 170-178 [PMID: 10450730]
10. 10 Chen K, Xu XW, Mou YP, Pan Y, Zhou YC, Zhang RC, Wu D. Systematic review and meta-analysis of laparoscopic and open gastrectomy for advanced gastric cancer. World J Surg Oncol 2013; 11: 182 [PMID: 23927773 DOI: 10.1186/1477-781 9-11-182]
11. 11 Fang C, Hua J, Li J, Zhen J, Wang F, Zhao Q, Shuang J, Du J. Comparison of long-term results between laparoscopy- assisted gastrectomy and open gastrectomy with D2 lymph- adenectomy for advanced gastric cancer. Am J Surg 2014; 208: 391-396 [PMID: 24534557 DOI: 10.1016/j.amjsurg.2013.09.028]
12. 12 Kim BS, Oh ST, Yook JH, Kim HS, Lee IS, Kim BS. Appro–priate gastrectomy resection margins for early gastric carci–noma. J Surg Oncol 2014; 109: 198-201 [PMID: 24249119 DOI: 10.1002/jso.23483]
13. 13 Wang W, Li Z, Tang J, Wang M, Wang B, Xu Z. Laparo–scopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. J Cancer Res Clin Oncol 2013; 139: 1721-1734 [PMID: 23990014 DOI: 10.1007/ s00432-013-1462-9]
14. 14 Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg 2013; 30: 119-129 [PMID: 23867588 DOI: 10.1159/000350877]
15. 15 Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the ran-domized Dutch gastric cancer group trial. J Clin Oncol 2004; 22: 2069-2077 [PMID: 15082726]
16. 16 Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, Sydes M, Fayers P. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79: 1522-1530 [PMID: 10188901]
17. 17 Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, An- naiah S, Suradkar K, Mehta S, Goel M. D2 lymphadenec- tomy is not only safe but necessary in the era of neoadju–vant chemotherapy. World J Surg Oncol 2013; 11: 31 [PMID: 23375104 DOI: 10.1186/1477-7819-11-31]
18. 18 Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C, Borasi A, Capussotti L, Fronda G, Morino M; Ita–lian Gastric Cancer Study Group. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014; 101: 23-31 [PMID: 24375296 DOI: 10.1002/bjs.9345]
19. 19 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines): Gas–tric Cancer. Version: Jan 2014
20. 20 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Ho- henberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with sur–gery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218 [PMID: 21060024 DOI: 10.1200/JCO.2009.26.6114]
21. 21 Basi A, Sohrabkhani S, Zamani F, Baghai-Wadji M, Rabiei N, Razavi SM, Ajdarkosh H. Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer. Int J Hematol Oncol Stem Cell Res 2013; 7: 24-28 [PMID: 24505539]
22. 22 Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, Munakata Y, Fukushima R, Kameda Y, Shi- moda T, Oba K, Sakamoto J. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally ad-vanced gastric cancer. Cancer Chemother Pharmacol 2013; 71: 1309-1314 [PMID: 23463482 DOI: 10.1007/s00280-013-2130-0]
23. 23 Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, Wang L. FOLFOX versus EOX as a neoadjuvant chemotherapy regi–men for patients with advanced gastric cancer. Exp Ther Med 2014; 7: 461-467 [PMID: 24396426]
24. 24 Ge L, Wang HJ, Yin D, Lei C, Zhu JF, Cai XH, Zhang GQ. Effectiveness of 5-flurouracil-based neoadjuvant chemo–therapy in locally-advanced gastric/gastroesophageal can–cer: a meta-analysis. World J Gastroenterol 2012; 18: 7384-7393 [PMID: 23326149 DOI: 10.3748/wjg.v18.i48.7384]
25. 25 Liao Y, Yang ZL, Peng JS, Xiang J, Wang JP. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of ran–domized, controlled trials. J Gastroenterol Hepatol 2013; 28: 777-782 [PMID: 23425049 DOI: 10.1111/jgh.12152]
26. 26 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992]
27. 27 Mirza A, Pritchard S, Welch I. The postoperative component of MAGIC chemotherapy is associated with improved prog–nosis following surgical resection in gastric and gastroo- esophageal junction adenocarcinomas. Int J Surg Oncol 2013; 2013: 781742 [PMID: 24163764 DOI: 10.1155/2013/781742]
28. 28 Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebre- ton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesopha–geal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]
29. 29 Boige V, Pignon J, Saint-Aubert B,Lasser P, Conroy T, Bouche O, Segol P, Bedenne L, Rougier R, Ychou M. Final results of a randomized trial comparing preoperative 5-fluo- rouracil (F)/cisplatin (P) to surgery alone in adenocarcino–ma of stomach and lower esophagus (ASLE): FNLCC AC- CORD07-FFCD 9703 trial. J Clin Oncol (Meeting Abstracts) 2007; 25 (suppl): abstr 4510
30. 30 Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, Wu Q, Zong XL, Ren H, Tang L, Zhang XP, Li JY, Hu Y, Shen L, Ji JF. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol 2012; 105: 793-799 [PMID: 22189752 DOI: 10.1002/jso.23009]
31. 31 Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Jensen K; GE Adenocarcinoma Meta–analysis Group. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stom–ach, gastroesophageal junction, and lower esophagus. Co–chrane Database Syst Rev 2013; 5: CD008107 [PMID: 23728671 DOI: 10.1002/14651858.CD008107]
32. 32 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741]
33. 33 Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012; 30: 2327-2333 [PMID: 22585691 DOI: 10.1200/ JCO.2011.36.7136]
34. 34 Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cispla–tin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012; 30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953]
35. 35 Fuchs CS, Tepper JE, Niedzwiecke D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarna- son GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 (abstract 4003). J Clin Oncol 2011; 29: 256s
36. 36 Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical re–section: a meta-analysis of randomized trials. Oncology 2014; 86: 79-85 [PMID: 24435019 DOI: 10.1159/000354641]
37. 37 Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial compar–ing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011; 29: 4387-4393 [PMID: 22010012 DOI: 10.1200/JCO.2011.36.5908]
38. 38 Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Di- nolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS. Comparison of the pharmacokinetics and pharmacody–namics of S-1 between Caucasian and East Asian patients. Cancer Sci 2011; 102: 478-483 [PMID: 21143703 DOI: 10.1111/ j.1349-7006.2010.01793.x]
39. 39 Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichi- nitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553 [PMID: 20159816 DOI: 10.1200/JCO.2009.25.4706]
40. 40 Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLAS–SIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-321 [PMID: 22226517 DOI: 10.1016/ S0140-6736(11)61873-4]
41. 41 Zhang XL, Shi HJ, Cui SZ, Tang YQ, Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resec–tion of gastric adenocarcinoma. Eur J Surg Oncol 2011; 37: 466-472 [PMID: 21414740 DOI: 10.1016/j.ejso.2011.01.027]
42. 42 Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, Lee JL, Kim TW, Yang DH, Jang SJ, Park YS, Lee YJ, Jung HY, Kim JH, Kim BS. Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Che- mother Pharmacol 2014; 73: 139-149 [PMID: 24162381 DOI: 10.1007/s00280-013-2332-5]
43. 43 Thuss-Patience PC, Hofheinz RD, Arnold D, Florschutz A, Daum S, Kretzschmar A, Mantovani-Loffler L, Bichev D, Breithaupt K, Kneba M, Schumacher G, Glanemann M, Schlattmann P, Reichardt P, Gahn B. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkolo- gie (AIO){dagger}. Ann Oncol 2012; 23: 2827-2834 [PMID: 22734012 DOI: 10.1093/annonc/mds129]
44. 44 Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hicke- son M, Artho G, Thirlwell MP. Perioperative docetaxel, cis–platin, and 5-fluorouracil (DCF) for locally advanced esoph–ageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol 2012; 23: 1512-1517 [PMID: 22039085 DOI: 10.1093/annonc/mdr465]
45. 45 Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hirabayashi N, Mikata S, Iwahashi M, Fuku-shima R, Takiguchi N, Miyashiro I, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Induction of a pathological com-plete response by four courses of neoadjuvant chemothera–py for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol 2014; 21: 213-219 [PMID: 23838904 DOI: 10.1245/s10434-013-3055-x]
46. 46 Kosaka T, Akiyama H, Makino H, Takagawa R, Kimura J, Ono H, Kunisaki C, Endo I. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally ad–vanced gastric cancer. Cancer Chemother Pharmacol 2014; 73: 281-285 [PMID: 24253176 DOI: 10.1007/s00280-013-2350-3]
47. 47 Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M, Cats A. Neo-adjuvant che–motherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011; 11: 329 [PMID: 21810227 DOI: 10.1186/1471-2407-11-329]
48. 48 Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39 [PMID: 24094768 DOI: 10.1016/S0140-6736(13)61719-5]
49. 49 Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzum–ab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open–label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
50. 50 Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araujo A, de Mello RA. Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013; 19: 6383-6397 [PMID: 24151357 DOI: 10.3748/wjg.v19.i38.6383]
51. 51 Qiu MZ, Li Q, Wang ZQ, Liu TS, Liu Q, Wei XL, Jin Y, Wang DS, Ren C, Bai L, Zhang DS, Wang FH, Li YH, Xu RH. HER2-positive patients receiving trastuzumab treat–ment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort ob–servation. Int J Cancer 2014; 134: 2468-2477 [PMID: 24155030 DOI: 10.1002/ijc.28559]
52. 52 Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, Hosein PJ. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res 2014; 34: 301-306 [PMID: 24403478]
53. 53 Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014; 110: 1163-1168 [PMID: 24473399 DOI: 10.1038/bjc.2014.18]
54. 54 Misawa K, Mochizuki Y, Ohashi N, Matsui T, Nakayama H, Tsuboi K, Sakai M, Ito S, Morita S, Kodera Y. A randomized phase III trial exploring the prognostic value of extensive in–traoperative peritoneal lavage in addition to standard treat–ment for resectable advanced gastric cancer: CCOG 1102 study. Jpn J Clin Oncol 2014; 44: 101-103 [PMID: 24287077 DOI: 10.1093/jjco/hyt157]